Aurobindo Pharma stock is under pressure, after the USFDA released details of the warning letter for the company’s New Jersey unit.
The warning letter was issued last month and now the USFDA has released the details of that warning letter. The USFDA says that methods, facilities, manufacturing, processing do not conform to current good manufacturing practice (CGMP).
It summarises significant violations of good manufacturing practice and they strongly recommend engaging a consultant.
To know more, watch this video.